Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 | Q09428 | 12/20 | 0.43 |
| ▸ | KCNJ11 | Q14654 | 12/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077623 | 0.99 | ABCC8 (0.43) | ABCC8KCNJ11KMT2AMEN1KDM4C | |
| SCHEMBL7067978 | 0.96 | ABCC8 (0.46) | ABCC8KCNJ11GRIA1GRIA2GRIA3 | |
| SCHEMBL7077745 | 0.93 | ABCC8 (0.42) | ABCC8KCNJ11GRIA1GRIA2GRIA3 | |
| SCHEMBL7590374 | 0.83 | ALDH1A1 (0.41) | ALDH1A1HPGDMAPT | |
| SCHEMBL7077783 | 0.83 | HTR5A (0.33) | HTR5A | |
| SCHEMBL7073665 | 0.83 | ABCC8 (0.36) | ABCC8KCNJ11HTR5AALDH1A1HPGD | |
| SCHEMBL7074727 | 0.81 | ABCC8 (0.40) | ABCC8KCNJ11KMT2AMEN1GRIA1 | |
| SCHEMBL7075417 | 0.80 | MEN1 (0.31) | ABCC8KCNJ11KMT2AMEN1KDM4C | |
| SCHEMBL7078790 | 0.79 | ABCC8 (0.44) | ABCC8KCNJ11GRIA1GRIA2GRIA3 | |
| SCHEMBL2344068 | 0.77 | ABCC8 (0.45) | ABCC8KCNJ11GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | claimed |
| US-20030125323-A1 | Use of selective potassium channel openers | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | US | claimed |
| US-20030109519-A1 | Use of selective potassium channel openers | NOVO NORDISK (DK) | 2003-06-12 | — | — | US | claimed |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | NOVO NORDISK A/S (DK) | 2002-03-21 | — | — | US | claimed |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | claimed |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | disclosed |
| US-20030125323-A1 | Use of selective potassium channel openers | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | US | disclosed |
| US-20030109519-A1 | Use of selective potassium channel openers | NOVO NORDISK (DK) | 2003-06-12 | — | — | US | disclosed |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | disclosed |
| US-6225310-B1 | Fused 1,2,4-thiadiazine derivatives, their preparation and use | NOVO NORDISK A/S (DK) | 2001-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125323-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ1, KCNJ2 | ABCC8 73/4885KCNJ11 1/4885KMT2A 1391/4885 |
| US-20030109519-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ2, KCNJ1 | ABCC8 63/4885KCNJ11 1/4885KMT2A 1399/4885 |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | KCNN3, KCNN1, KCNN2 | ABCC8 944/4885KCNJ11 7/4885KMT2A 1098/4885 |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | CD69, IAPP, CD4 | ABCC8 3372/4885KCNJ11 1274/4885KMT2A 2399/4885 |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | KCNN3, KCNN2, KCNN1 | ABCC8 985/4885KCNJ11 13/4885KMT2A 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.